News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,431 Results
Type
Article (13591)
Company Profile (110)
Press Release (247730)
Section
Business (87978)
Career Advice (462)
Deals (15327)
Drug Delivery (64)
Drug Development (36553)
Employer Resources (49)
FDA (6261)
Job Trends (6187)
News (150093)
Policy (14016)
Tag
Academia (437)
Alliances (23108)
Alzheimer's disease (352)
Approvals (6255)
Artificial intelligence (61)
Bankruptcy (143)
Best Places to Work (4327)
Biotechnology (44)
Breast cancer (42)
Cancer (315)
Career advice (405)
Cell therapy (44)
Clinical research (30424)
Collaboration (155)
Compensation (62)
COVID-19 (747)
C-suite (52)
Data (343)
Diabetes (53)
Diagnostics (1236)
Drug pricing (57)
Earnings (31566)
Employer resources (43)
Events (36761)
Executive appointments (173)
FDA (6441)
Funding (108)
Gene therapy (59)
GLP-1 (292)
Government (1268)
Healthcare (3537)
Infectious disease (765)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5820)
Job creations (2050)
Job search strategy (372)
Layoffs (167)
Legal (3413)
Lung cancer (46)
Manufacturing (99)
Medical device (1265)
Medtech (1267)
Mergers & acquisitions (9542)
Metabolic disorders (168)
Neuroscience (450)
NextGen Class of 2024 (1580)
Non-profit (591)
Northern California (436)
Obesity (101)
Opinion (109)
Patents (53)
People (28468)
Pharmaceutical (64)
Phase I (7914)
Phase II (12862)
Phase III (11558)
Pipeline (183)
Policy (45)
Postmarket research (1400)
Preclinical (3166)
Radiopharmaceuticals (117)
Rare diseases (90)
Real estate (2631)
Regulatory (9827)
Research institute (564)
Resumes & cover letters (55)
Southern California (435)
Startups (1626)
United States (4283)
Vaccines (112)
Weight loss (78)
Date
Today (49)
Last 7 days (264)
Last 30 days (1264)
Last 365 days (12724)
2024 (11634)
2023 (14254)
2022 (19564)
2021 (20083)
2020 (19048)
2019 (14905)
2018 (11730)
2017 (13911)
2016 (13135)
2015 (15479)
2014 (12428)
2013 (10599)
2012 (11397)
2011 (11924)
2010 (10891)
Location
Africa (313)
Arizona (42)
Asia (19796)
Australia (2561)
California (1010)
Canada (602)
China (111)
Colorado (42)
Connecticut (42)
Europe (38792)
Florida (152)
Illinois (111)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (155)
Massachusetts (882)
Minnesota (56)
New Jersey (422)
New York (279)
North Carolina (278)
Northern California (436)
Pennsylvania (286)
South America (498)
Southern California (435)
Texas (138)
Virginia (41)
Washington State (71)
261,431 Results for "jcr pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
JCR Pharmaceuticals Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA
October 31, 2024
·
4 min read
News
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress
October 16, 2024
·
2 min read
Business
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
JCR Pharmaceuticals Co., Ltd. announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo ® Technology.
December 21, 2023
·
4 min read
News
JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress
October 23, 2024
·
5 min read
Business
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo ® Technology for Neurodegenerative Disease in Research Collaboration with Alexion.
March 19, 2024
·
4 min read
JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024
JCR Pharmaceuticals Co., Ltd. announced today that it will present six presentations at the 20th Annual WORLD Symposium ™ 2024, to be held February 4-9, 2024 in San Diego, Calif.
January 25, 2024
·
13 min read
Genetown
Modalis and JCR Pharmaceuticals enter into joint research agreement
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) today announced that it has entered into a joint research agreement with JCR Pharmaceuticals Co., Ltd. (JCR Pharmaceuticals) on joint evaluation of the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target.
December 12, 2023
·
2 min read
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
JCR Pharmaceuticals’ Research Presentations at WORLD Symposium ™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders.
February 14, 2024
·
21 min read
Business
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida: “JCR”) announces that it has signed a Research Collaboration, Option and License Agreement with Alexion, AstraZeneca Rare Disease (“Alexion”) for the development of novel oligonucleotide therapeutics to support targeted delivery to certain tissues or organs using J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB)-penetrating technology.
December 21, 2023
·
5 min read
Drug Development
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the first patient in the Phase I/II clinical trial with Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome Type A) has been dosed with JR‑441, a blood-brain barrier (BBB) penetrating form of heparan N-sulfatase that was developed using JCR’s proprietary J-Brain Cargo ® BBB-penetrating technology.
November 10, 2023
·
6 min read
1 of 26,144
Next